(NASDAQ: PRTA) Prothena Public Co's forecast annual revenue growth rate of 13.39% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Prothena Public Co's revenue in 2025 is $135,157,000.On average, 4 Wall Street analysts forecast PRTA's revenue for 2025 to be $4,335,763,400, with the lowest PRTA revenue forecast at $2,739,793,384, and the highest PRTA revenue forecast at $8,074,047,300. On average, 4 Wall Street analysts forecast PRTA's revenue for 2026 to be $5,732,573,583, with the lowest PRTA revenue forecast at $1,171,813,398, and the highest PRTA revenue forecast at $11,571,724,590.
In 2027, PRTA is forecast to generate $11,301,513,141 in revenue, with the lowest revenue forecast at $2,423,828,999 and the highest revenue forecast at $20,566,213,283.